Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
NCT ID: NCT03420014
Last Updated: 2023-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
114 participants
INTERVENTIONAL
2018-12-27
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
NCT04032964
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
NCT04650984
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
NCT00484341
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
NCT04733183
Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
NCT04055753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective of the trial is to evaluate if L19TNF in combination with doxorubicin (Arm 2) given for metastatic leiomyosarcoma improves efficacy measured as progression free survival, as compared to doxorubicin alone (Arm 1).
Anti-cancer activity will be assessed every 6 weeks during therapy and every 12 weeks thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Doxorubicin
Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
Doxorubicin
75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
Arm 2: L19TNF plus doxorubicin
Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.
Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF.
L19TNF plus doxorubicin
13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxorubicin
75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
L19TNF plus doxorubicin
13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥ 16 years. Patients under 18 years, should be fully grown (proof of fused growth plates).
2. Patients with histological evidence of stage IV metastatic high-grade leiomyosarcoma (grade 2 - 3 according to the Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading system) not amenable to curative treatment with surgery or radiotherapy.
3. Patients must have at least one unidimensionally measurable lesion by computed tomography as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1. If only 1 lesion is present at screening this lesion should not have been irradiated during previous treatments.
4. Life expectancy of at least 3 months in the judgment of the investigator.
5. ECOG ≤ 1.
6. Documented negative test for HIV, HBV and HCV. For HBV serology, the determination of HBsAg and anti-HBcAg-Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
7. Female patients: negative serum pregnancy test for women of childbearing potential (WOCBP)\* within 14 days of starting treatment. WOCBP must agree to use, from the screening to six months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence.
8. Male patients: Male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g., condom with spermicidal gel). Double-barrier contraception is required.
9. Informed consent signed and dated to participate in the study.
10. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
* Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy).
Exclusion Criteria
1. Prior therapy (except surgery and radiation) for unresectable or metastatic malignant soft tissue sarcoma (STS).
2. Patients with primary tumor localized to the extremities and a single resectable synchronous distant metastatic lesion.
3. Patients eligible for neoadjuvant preoperative treatment.
4. Previous treatment with anthracycline-containing chemotherapy.
5. Radiotherapy within 4 weeks prior to start of therapy.
6. Known history of allergy to TNFα, anthracyclines or other intravenously (IV) administered human proteins/peptides/antibodies.
7. Absolute neutrophil count (ANC) \< 1.5 x 109/L, platelets \< 100 x 109/L and haemoglobin (Hb) \< 9.0 g/dl.
8. Chronically impaired renal function as expressed by creatinine clearance \< 60 mL/min or serum creatinine \> 1.5 ULN.
9. Inadequate liver function (ALT, AST, GGT, ALP or total bilirubin ≥ 1.5 x ULN) or total bilirubin ≥ 1.5 x ULN).
10. International normalized ratio (INR) \> 1.5 ULN.
11. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
12. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
13. Heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
14. Left Ventricular Ejection Fraction (LVEF) \< 50%.
15. Clinically significant cardiac arrhythmias or requiring permanent medication.
16. Abnormalities observed during baseline ECG and Echocardiogram investigations that are considered as clinically significant by the investigator. Subjects with current, or a history of QT/QTc prolongation would be excluded. In particular:
* patients with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of QTc \>480 milliseconds using Fredricia's QT correction formula) are excluded;
* patients with a history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of prolonged QT syndrome) are excluded;
* patients who require the use of concomitant medications that prolong the QT/QTc interval are excluded.
17. Uncontrolled hypertension, despite optimal therapy.
18. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
19. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
20. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of study treatment.
21. Pregnancy or breast-feeding.
22. Requirement of chronic administration of corticosteroids or other immunosuppressant drugs. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
23. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
24. Known active or latent tuberculosis (TB).
25. Concurrent malignancies other than soft tissue sarcoma (STS), unless the patient has been disease-free for at least 2 years.
26. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
27. Serious, non-healing wound, ulcer or bone fracture.
28. Allergy to study medication or excipients in study medication.
29. Concurrent therapy with anticoagulants.
30. Concurrent use of other anti-cancer treatments or agents other than study medication.
31. Any recent live vaccination within 4 weeks prior to treatment or plan to receive vaccination during the study.
16 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philogen S.p.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott H. Okuno, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic, Rochester, MN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Hospital
Phoenix, Arizona, United States
Sarcoma Oncology Research Center (SORC) Cancer Center of Southern California
Santa Monica, California, United States
Mayo Clinic Hospital
Jacksonville, Florida, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University
St Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey 195 Little Albany Street New Brunswick, NJ 08901 Room 2031
New Brunswick, New Jersey, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Seattle Cancer Care Alliance 825 Eastlake Ave. E. Seattle, WA 98109 Mail Stop CE2-128
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mahesh Seetharam, MD
Role: primary
Sant P Chawla, MD
Role: primary
Scott Okuno, MD
Role: primary
Mia Weiss, MD
Role: primary
Sarah Weiss, MD
Role: primary
David A Liebner, MD
Role: primary
Lee Cranmer, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PH-L19TNFDOX2-02/17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.